TRCT
APRE icon

Tower Research Capital (TRC)’s Aprea Therapeutics APRE Stock Holding History

Tower Research Capital (TRC)’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.88K Sell
3,590
-1,537
-30% -$1.28K ﹤0.01% 4607
2026
Q1 		$3.91K Sell
5,127
-2,700
-34% -$2.12K ﹤0.01% 4251
2025
Q4 		$6.68K Buy
7,827
+7,259
+1,278% +$8.91K ﹤0.01% 4056
2025
Q3 		$838 Sell
568
-2,395
-81% -$3.94K ﹤0.01% 4927
2025
Q2 		$5.01K Sell
2,963
-363
-11% -$619 ﹤0.01% 4237
2025
Q1 		$6.79K Buy
3,326
+1,848
+125% +$5.79K ﹤0.01% 4013
2024
Q4 		$4.86K Buy
1,478
+163
+12% +$545 ﹤0.01% 4385
2024
Q3 		$3.62K Sell
1,315
-1,415
-52% -$4.99K ﹤0.01% 4811
2024
Q2 		$11.1K Buy
2,730
+1,604
+142% +$8.27K ﹤0.01% 4103
2024
Q1 		$7.53K Buy
1,126
+578
+105% +$3.59K ﹤0.01% 4184
2023
Q4 		$2.58K Sell
548
-1,199
-69% -$4.91K ﹤0.01% 5193
2023
Q3 		$7.28K Sell
1,747
-1,578
-47% -$5.75K ﹤0.01% 4484
2023
Q2 		$10.5K Buy
3,325
+1,848
+125% +$6.89K ﹤0.01% 4116
2023
Q1 		$7K Sell
1,477
-902
-38% -$6.66K ﹤0.01% 4713
2022
Q4 		$15K Buy
2,379
+1,263
+113% +$13.3K ﹤0.01% 3398
2022
Q3 		$15K Sell
1,116
-1,252
-53% -$22.2K ﹤0.01% 4151
2022
Q2 		$36K Buy
2,368
+696
+42% +$16K ﹤0.01% 3173
2022
Q1 		$62K Buy
1,672
+571
+52% +$23.4K ﹤0.01% 2556
2021
Q4 		$64K Buy
1,101
+921
+512% +$81.4K ﹤0.01% 2563
2021
Q3 		$18K Sell
180
-144
-44% -$13.1K ﹤0.01% 3800
2021
Q2 		$31K Sell
324
-179
-36% -$16.5K ﹤0.01% 3443
2021
Q1 		$51K Buy
503
+320
+175% +$37.3K ﹤0.01% 3102
2020
Q4 		$18K Sell
183
-250
-58% -$119K ﹤0.01% 3924
2020
Q3 		$208K Buy
433
+360
+493% +$201K ﹤0.01% 2540
2020
Q2 		$56K Buy
+73
New +$47.9K ﹤0.01% 2958

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Tower Research Capital (TRC)'s APRE Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Aprea Therapeutics (APRE) stake by 30% in Q2 2026, selling an estimated $1.28K and leaving 3,590 shares worth $2.88K. The position accounts for ﹤0.01% of the portfolio, ranked #4607.

Tower Research Capital (TRC) first reported a position in APRE in Q2 2020 and has held it in 25 quarters since. The position peaked at $208K in Q3 2020. 28 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

  • Tower Research Capital (TRC) held 3,590 shares of Aprea Therapeutics worth $2.88K as of Q2 2026.
  • Tower Research Capital (TRC) sold 1,537 Aprea Therapeutics shares in Q2 2026, an estimated $1.28K.
  • Aprea Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4607 holding.
  • Tower Research Capital (TRC) first reported a position in Aprea Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Tower Research Capital (TRC)'s Aprea Therapeutics position peaked at $208K in Q3 2020.
  • 28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.